Source comparison
Receptor Mechanisms: GHRH Amplification vs Ghrelin Mimicry
CJC-1295 no DAC binds to growth hormone releasing hormone receptors (GHRHR) located on somatotroph cells in the anterior pituitary. When GHRH receptors are activated, they trigger adenylyl cyclase, which converts ATP to cyclic AMP (cAMP). The second messenger
This comparison does not assign a generated winner or score.
- CJC-1295 no DAC binds to growth hormone releasing hormone receptors (GHRHR) located on somatotroph cells in the anterior pituitary. When GHRH receptors are activated, they trigger adenylyl cyclase, which converts ATP to cyclic AMP (cAMP). The second messenger that ultimately signals the pituitary to release stored growth hormone into circulation. Modified GRF (1-29) is structurally identical to native GHRH(1-29) except for four amino acid substitutions at positions 2, 8, 15, and 27, which protect the peptide from enzymatic degradation by dipeptidyl peptidase-4 (DPP-4). This resistance to DPP-4 extends the peptide's active window from under 7 minutes (native GHRH) to approximately 30 minutes, allowing a single subcutaneous injection to amplify one complete endogenous GH pulse.
- GHRP-2 Acetate operates through an entirely separate pathway. It's a synthetic hexapeptide (His-D-Trp-Ala-Trp-D-Phe-Lys-NH2) that binds to the ghrelin receptor, officially designated GHS-R1a (growth hormone secretagogue receptor type 1a). Ghrelin receptors exist in both the hypothalamus and the pituitary, which means GHRP-2 triggers GH release through two simultaneous mechanisms: directly at the pituitary level (like CJC-1295 no DAC) and indirectly by reducing somatostatin tone in the hypothalamus. Somatostatin is the inhibitory hormone that normally suppresses GH secretion between pulses. By blocking somatostatin signaling, GHRP-2 removes the brake that would otherwise limit how much GH the pituitary can release in response to GHRH stimulation.
- This dual-pathway action is why GHRP-2 administered alone produces sharper, higher-amplitude GH spikes than CJC-1295 no DAC used alone. A 100mcg dose of GHRP-2 can elevate plasma GH levels to 10–25 ng/mL within 20–30 minutes in healthy adults, compared to 5–15 ng/mL with 100mcg of Modified GRF. But here's the critical point: when both peptides are administered together, the GH response is synergistic rather than additive. Research published in the Journal of Clinical Endocrinology & Metabolism found that combined GHRH + GHRP administration produced GH levels 3–5 times higher than the sum of each peptide's individual effect. Because GHRP-2 removes somatostatin inhibition at the exact moment CJC-1295 no DAC is amplifying GHRH signaling.